Annex to 16-19 June 2025 CHMP Minutes
Submitted by Anonymous (not verified) on 10 February 2026 - 13:20
Annex to 16-19 June 2025 CHMP Minutes
Minutes of the CHMP meeting 16-19 June 2025
Submitted by Anonymous (not verified) on 10 February 2026 - 13:19
Minutes of the CHMP meeting 16-19 June 2025
Article 57 product data
Submitted by Anonymous (not verified) on 10 February 2026 - 12:30
Article 57 product data
List of eligible industry stakeholder organisations
Submitted by Anonymous (not verified) on 10 February 2026 - 12:20
List of eligible industry stakeholder organisations
Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)
Submitted by Anonymous (not verified) on 10 February 2026 - 11:45
Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)
Ledipasvir/sofosbuvir product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 10 February 2026 - 10:00
Ledipasvir/sofosbuvir product-specific bioequivalence guidance
Human medicines European public assessment report (EPAR): Piasky, crovalimab, Date of authorisation: 22/08/2024, Revision: 3, Status: Authorised
Submitted by Anonymous (not verified) on 10 February 2026 - 9:30
Human medicines European public assessment report (EPAR): Piasky, crovalimab, Date of authorisation: 22/08/2024, Revision: 3, Status: Authorised
Validation checklist for Type II quality variations
Submitted by Anonymous (not verified) on 10 February 2026 - 7:48
Validation checklist for Type II quality variations
Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 9 February 2026 - 16:50
Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 3, Status: Authorised
Submitted by Anonymous (not verified) on 9 February 2026 - 16:46
Human medicines European public assessment report (EPAR): Lytenava, bevacizumab, Date of authorisation: 27/05/2024, Revision: 3, Status: Authorised